Fundraising FoxMapLight Therapeutics
NASDAQ: MPLTRedwood City, US · Founded 2018 · Delaware corporation · 4 known investors
Find your way into MapLight Therapeutics
Sign up to see every warm intro you have to MapLight Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MapLight Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease. The company's lead program is a fixed-dose combination targeting muscarinic receptors in development for schizophrenia and Alzheimer's disease psychosis.
Founders & leadership
MapLight Therapeutics was founded in 2018 by Anatol Kreitzer.
AK
Anatol KreitzerFounder
KH
Kristopher HansonExecutive
JL
James LillieExecutive
CA
Christopher A. KroegerPresident, Chief Executive Officer and Director
EP
Erin Pennock FoffChief Medical OfficerNeurologist with over 15 years of experience in basic science and clinical trials, including subspecialty focus on cognitive neurology and neurodegenerative diseases. Now Chief Medical Officer at MapLight Therapeutics, a biopharmaceutical company developing targeted treatments for central nervous system disorders.
RM
Robert MalenkaNamed on SEC filing
Board
GP
George PavlovBoard director
PB
Peter BisgaardBoard director
JT
TG
Timothy GarnettBoard director
Investors · 4
Avego BioScience Capitallisted by Avego BioScience CapitalAlpharetta
How we know: Avego BioScience Capital's portfolio page · Not right? Tell us
Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco
How we know: Pivotal Life Sciences's portfolio page · Not right? Tell us
ForbionreportedNaardenvia Nanna Lüneborg · board
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Novo HoldingsreportedCopenhagen · $1.1M – $54M
How we know: the S-1 prospectus · Not right? Tell us
Funding
SEC filings, press & company announcements$356.2M disclosed across 6 of 11 rounds · 1900–2026
- Undisclosed amountcolocación privadaAug 2026Source ↗
▶$188.2MraisedJul 2025 · 19 investors · BiotechnologyRule 506(b)
▶$188.2MraisedJul 2025 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kristopher HansonExecutive Officer
- Timothy GarnettDirector
- George PavlovDirector
- Peter BisgaardDirector
- Erin FoffExecutive Officer
- Anatol KreitzerExecutive Officer
- Jim TrenkleDirector
- James LillieExecutive Officer
- Maria WalkerDirector
- Christopher A KroegerExecutive Officer, Director
- Jonathan GillisExecutive Officer
- Vishwas SetiaExecutive Officer
- Nanna LuneborgDirector
- Offering amount
- $372.4M
- Amount sold
- $188.2M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$105MraisedNov 2023 · 12 investors · BiotechnologyRule 506(b)
▶$105MraisedNov 2023 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert MalenkaDirector
- Jim TrenkleDirector
- Peter BisgaardDirector
- Kristopher HansonExecutive Officer
- George PavlovDirector
- Charmaine LykinsExecutive Officer
- Anatol KreitzerExecutive Officer
- Erin FoffExecutive Officer
- Jonathan GillisExecutive Officer
- James LillieExecutive Officer
- Timothy GarnettDirector
- Christopher A KroegerExecutive Officer, Director
- Offering amount
- $225M
- Amount sold
- $105M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$12MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$12MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter BisgaardDirector
- Christopher A KroegerExecutive Officer, Director
- Erin FoffExecutive Officer
- James LillieExecutive Officer
- George PavlovDirector
- Robert MalenkaDirector
- Anatol KreitzerExecutive Officer
- Jonathan GillisExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$30MraisedMar 2021 · 2 investors · BiotechnologyRule 506(b)
▶$30MraisedMar 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher A KroegerExecutive Officer, Director
- George PavlovDirector
- Robert MalenkaDirector
- Anatol KreitzerExecutive Officer
- Peter BisgaardDirector
- Jonathan GillisExecutive Officer
- James LillieExecutive Officer
- Offering amount
- $60M
- Amount sold
- $30M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$16MraisedSep 2019 · 2 investors · BiotechnologyRule 506(b)
▶$16MraisedSep 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan GillisExecutive Officer
- Peter BisgaardDirector
- James LillieExecutive Officer
- Robert MalenkaDirector
- Christopher A KroegerExecutive Officer, Director
- George PavlovDirector
- Offering amount
- $16M
- Amount sold
- $16M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5MraisedMar 2019 · 2 investors · BiotechnologyRule 506(b)
▶$5MraisedMar 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher A KroegerExecutive Officer, Director
- Robert MalenkaDirector
- James LillieExecutive Officer
- George PavlovDirector
- Peter BisgaardDirector
- Jonathan GillisExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does MapLight Therapeutics do?
- MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease. The company's lead program is a fixed-dose combination targeting muscarinic receptors in development for schizophrenia and Alzheimer's disease psychosis.
- Who founded MapLight Therapeutics?
- MapLight Therapeutics was founded by Anatol Kreitzer in 2018.
- Who are MapLight Therapeutics's investors?
- MapLight Therapeutics's investors include Avego BioScience Capital, Pivotal Life Sciences, Forbion, Novo Holdings.
- How much funding has MapLight Therapeutics raised?
- MapLight Therapeutics has disclosed $356.2M raised across 6 of its 11 known rounds.
- Where is MapLight Therapeutics headquartered?
- MapLight Therapeutics is headquartered in Redwood City, US.